NCT04685499 - Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

March 8, 2022

Study Completion Date

June 3, 2022

Conditions

Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

Interventions

DRUG

OBP-301

Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.

DRUG

Pembrolizumab

Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year

Trial Locations (1)

Weill Cornell Medicine, New York